The research team, led by Yiyue Xu and corresponding author Linlin Wang, systematically searched three major biomedical databases, PubMed, Embase, and Web of Science, for phase III randomized controlled trials published between January 1, 2015, and August 5, 2026. Their inclusion criteria were deliberately strict: only trials evaluating first-line immune checkpoint inhibitor plus chemotherapy regimens in advanced solid tumors qualified. The effort yielded an extraordinary evidence base of 58 phase III randomized controlled trials encompassing 36,664 patients, with regimens combining chemotherapy with 20 distinct immune checkpoint inhibitors across multiple tumor types. That scale matters, because individual trials typically compare a single immunotherapy against chemotherapy alone within one cancer type, leaving clinicians to guess how, say, a PD-L1 inhibitor used in lung cancer might compare on safety with a CTLA-4 pathway agent deployed elsewhere.

The methodological engine of the study is the network meta-analysis, a statistical framework that allows simultaneous comparison of multiple treatments even when they have never been tested against each other directly. By building a network of evidence connected through common comparators, in this case chemotherapy plus placebo, the researchers could estimate odds ratios with 95 percent credibility intervals for every pairwise comparison in the network. They then applied Bayesian ranking probabilities and calculated the surface under the cumulative ranking curve, known as SUCRA, to produce a league table of regimens ordered by safety. The primary outcome was the occurrence of grade 3 or higher immune-related adverse events, the severe toxicities that arise when unleashed immune systems attack healthy tissue. Secondary safety endpoints included all-grade immune-related adverse events and both severe and all-grade treatment-related adverse events more broadly.

The headline finding concerns adebrelimab, an anti-PD-L1 antibody, which emerged as the most favorably ranked regimen for severe immune-related adverse events. Adebrelimab plus chemotherapy achieved the highest SUCRA value in this domain, at 76.27 percent, indicating the strongest cumulative ranking probability among the 17 immune checkpoint inhibitor and chemotherapy regimens analyzed for this outcome. Notably, its pooled odds ratio against placebo plus chemotherapy was 1.62 with a 95 percent credibility interval of 0.28 to 9.83, an interval that crosses one, meaning the analysis could not statistically distinguish its severe immune toxicity risk from chemotherapy alone. For patients and clinicians weighing the trade-off between efficacy and immune toxicity, that profile represents a meaningful signal, though the wide interval also underscores the statistical uncertainty inherent in even the largest networks.

When the researchers turned to the broader toxicity categories, different agents rose to the top. Avelumab plus chemotherapy ranked highest for both all-grade immune-related adverse events and all-grade treatment-related adverse events, suggesting that while this regimen may produce more frequent lower-grade side effects, its overall tolerability profile compared favorably across the network. Meanwhile, regimens built around durvalumab and penpulimab showed the most favorable safety profiles for grade 3 or higher treatment-related adverse events, the severe toxicities of any cause attributable to treatment. The fact that different drugs top different safety categories is itself an important result: it demonstrates that safety is not a single dimension but a multidimensional profile, and the optimal choice may depend on which toxicity domain matters most for a given patient.

Understanding why these differences exist requires a brief tour of immunopharmacology. Immune checkpoint inhibitors work by blocking inhibitory receptors, such as PD-1, PD-L1, and CTLA-4, that normally restrain T-cell activity. Removing these brakes allows immune cells to attack tumors, but the same mechanism can trigger inflammation in the skin, gut, liver, lungs, and endocrine organs, producing the immune-related adverse events that define this drug class. The degree and character of immune activation vary substantially between molecules, depending on target, binding affinity, antibody engineering, and pharmacokinetics. When combined with cytotoxic chemotherapy, which carries its own burden of myelosuppression, nausea, and neuropathy, the resulting toxicity profile reflects a complex interplay that randomized trials rarely dissect in comparative terms. A network meta-analysis of this scale is precisely the tool needed to bring that hidden structure into view.

The rigor of the underlying evidence was assessed using the Cochrane Risk of Bias 2 tool, the current standard for evaluating randomized trials, which judges bias across domains including the randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting. By restricting inclusion to phase III trials, the most definitive study design in oncology, the authors minimized the risk that their rankings reflect artifacts of small or preliminary studies. The Bayesian framework additionally allows uncertainty to propagate through the entire network, so that rankings are expressed as probabilities rather than false certainties. Still, the authors and outside observers alike should note the limitations inherent to any such synthesis: trials enrolled different tumor types, used varying chemotherapy backbones, and applied somewhat heterogeneous toxicity grading, all of which can introduce transitivity assumptions that may not hold perfectly across the network.

The clinical implications are considerable. Immune checkpoint inhibitor plus chemotherapy combinations are now standard first-line therapy for multiple advanced solid tumors, including non-small cell lung cancer, and their use continues to expand. With 20 distinct checkpoint inhibitors now validated in this setting, oncologists face a genuine selection problem, and until now the comparative safety evidence has been fragmented across hundreds of individual trials. Severe immune-related adverse events are not merely statistical inconveniences; they can require high-dose corticosteroids, permanent drug discontinuation, hospitalization, and in rare cases prove fatal. A regimen ranking that identifies adebrelimab, avelumab, durvalumab, and penpulimab as comparatively favorable across different safety domains gives clinicians an evidence-based starting point for individualizing treatment, particularly for patients with preexisting autoimmune disease, organ transplants, or frailty who may tolerate immune toxicity poorly.

The study also carries implications for drug development and health policy. Regulators and guideline committees increasingly demand comparative rather than merely placebo-controlled evidence, and SUCRA-based rankings of this kind can inform which agents deserve prioritization in head-to-head trials, which combinations warrant preferential pricing negotiations, and where post-marketing surveillance should concentrate. The authors report no funding or competing interests, and the analysis was conducted by a radiation oncology department team, reflecting the growing recognition that safety, not only survival, defines the value of modern cancer therapy.

Caveats remain, and the authors are careful not to overstate them away. The credibility interval around adebrelimab’s odds ratio is wide, rankings depend on the set of trials available through August 2026, and the analysis addresses safety rather than efficacy, meaning the safest regimen is not automatically the best one for a given cancer. The article was published as a peer-reviewed, citable version carrying a permanent DOI, subject to further editorial processing. Even so, the work stands as a landmark synthesis: by pooling 58 phase III trials and nearly 37,000 patients into a single coherent network, it converts a decade of scattered toxicity data into an actionable hierarchy, and it signals a maturing of immuno-oncology from the era of proving that these drugs work to the more nuanced task of choosing precisely the right one for each patient.

Subject of Research: Comparative safety of immune checkpoint inhibitor plus chemotherapy first-line regimens for solid tumors

Article Title: Comparative safety of immune checkpoint inhibitor combined with chemotherapy as first-line treatment for solid tumors: a systematic review and network meta–analysis

Article References: Xu, Y., Li, B., Gao, A., Zhao, Q., Yang, L., & Wang, L. (2026). Comparative safety of immune checkpoint inhibitor combined with chemotherapy as first-line treatment for solid tumors: a systematic review and network meta–analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17007-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17007-w

Keywords: immune checkpoint inhibitors, chemotherapy, network meta-analysis, immune-related adverse events, treatment-related adverse events, solid tumors, phase III trials, adebrelimab, avelumab, durvalumab, penpulimab, drug safety

The TKI era delivered incremental but real gains. Lenvatinib emerged as a non-inferior first-line alternative to sorafenib, while regorafenib, cabozantinib, and the anti-VEGFR-2 antibody ramucirumab — the latter reserved for patients with alpha-fetoprotein levels of at least 400 ng/mL — extended survival after sorafenib failure. Yet the ceiling was low: median life expectancy on first-line TKI therapy rarely exceeded 12 to 13 months. Progressive liver dysfunction, clinical decompensation, and the difficulty of tolerating TKIs long-term exposed a fundamental limitation. Immune checkpoint inhibitors (ICIs) tested as monotherapy also failed to beat sorafenib in phase III studies, leaving the field at an impasse until combination immunotherapy arrived.

The turning point came with regimens that pair PD-1 pathway blockade with either VEGF inhibition or CTLA-4 inhibition. Median overall survival for untreated advanced HCC patients, once roughly six months, climbed to between 16 and 23 months in contemporary phase III trials — a leap accompanied by higher response rates, better safety profiles, and improved quality of life. Four pivotal trials now define first-line care. IMbrave150 showed atezolizumab plus bevacizumab (A + B) achieved a median overall survival of 19.2 months versus 13.4 months for sorafenib, with an objective response rate of 30% versus 11%, though six grade 5 bleeding events in the combination arm underscored the need for baseline endoscopic varices screening. HIMALAYA demonstrated that a single priming dose of tremelimumab plus monthly durvalumab (the STRIDE regimen) improved median survival to 16.4 months, with striking five-year survival of 19.6% compared with 9.4% for sorafenib.

CheckMate 9DW added a third option, combining ipilimumab induction with nivolumab maintenance against a control arm dominated by lenvatinib. Median overall survival reached 23.7 months versus 20.6 months, with a 36% response rate and a 48-month survival rate of 31% versus 18%. Notably, early deaths from hepatic events caused the survival curves to cross within the first six months, a reminder that close monitoring for liver decompensation is essential. The fourth positive trial, CARES-310, paired camrelizumab with the TKI rivoceranib and achieved the highest hazard ratio benefit (0.64) and a 23.8-month median survival — but with grade 3–4 toxicity in 81% of patients and a predominantly Asian, hepatitis B-driven population, its results are difficult to extrapolate to Europe, where alcohol-related liver disease, hepatitis C, and metabolic dysfunction-associated steatohepatitis (MASH) predominate.

Underlying liver disease aetiology was once thought to blunt immunotherapy efficacy, particularly in MASH-related HCC, but subsequent analyses have been inconsistent, and current European Society for Medical Oncology (ESMO) guidelines recommend the approved regimens regardless of aetiology. A thornier question concerns patients with Child-Pugh B liver dysfunction, who were largely excluded from phase III trials. Evidence from CheckMate 040 cohort 5 — where nivolumab achieved a 12% response rate and 7.6-month median survival in 49 Child-Pugh B7–B8 patients — and from a meta-analysis of 22 studies suggests immunotherapy is not absolutely contraindicated, though survival is markedly worse than in patients with preserved liver function. The authors stress that the cause of hepatic decline, whether tumour burden or decompensated cirrhosis, must be weighed case by case, ideally with refined tools such as the ALBI grade and within multidisciplinary team consensus.

Managing immune-related liver injury has itself become a core clinical skill. Because HCC arises on a backdrop of chronic liver disease, immune-mediated hepatotoxicity occurs earlier and more frequently than in other solid tumours, and diagnosis is complicated by the absence of specific criteria and by baseline liver test abnormalities. Most cases resolve without permanent discontinuation, but fatal hepatic toxicities have been reported, making vigilant monitoring and early multidisciplinary involvement non-negotiable elements of modern care.

What happens after first-line immunotherapy fails remains one of the field’s largest unmet needs. ESMO guidelines recommend only TKIs — sorafenib, lenvatinib, regorafenib, or cabozantinib — or ramucirumab in the second line, regardless of prior immunotherapy exposure. Observational data from the European LEVIATHAN registry favour lenvatinib over sorafenib after A + B failure (progression-free survival of 5.5 versus 2.6 months), and single-arm Asian phase II trials support regorafenib and cabozantinib in this setting. The recent IMbrave251 trial, though negative for its primary endpoint, provided the first randomised phase III benchmark for TKI monotherapy after first-line immunotherapy: 12.5-month overall survival and 4.8-month progression-free survival in the TKI-only arm. Crucially, no immunotherapy agent holds European approval in the second line — a stark contrast with the United States, where pembrolizumab and ipilimumab plus nivolumab are licensed after TKI failure. Off-label immunotherapy use in Europe therefore depends on institutional policies and is often not reimbursed, pushing costs onto hospital budgets, insurers, or patients themselves.

Access inequity emerges as the review’s most provocative theme. Although the European Medicines Agency grants EU-wide marketing authorisation, national reimbursement decisions vary enormously. Atezolizumab plus bevacizumab and the STRIDE regimen are now reimbursed in 23 and 18 European countries respectively, but ipilimumab plus nivolumab — EMA-approved in March 2025 — was, more than a year later, reimbursed in only one country, Germany. During 2016–2021, compliance with the EU’s recommended 180-day reimbursement deadline ranged from 100% in Germany to just 3% in Belgium. Molecular profiling offers little help in personalising choices: no genomic alteration in HCC reaches the top tiers of the ESMO ESCAT framework, and in the French Genomic Programme only 3 of 135 HCC patients were successfully matched to a targeted therapy. Emerging predictors — tumour immune contexture signatures, the CRAFITY score combining AFP and C-reactive protein, radiomic machine-learning models, and gut microbiome profiles — show promise but await prospective validation.

Meanwhile, European practice is quietly diverging from guidelines in the locoregional arena. Trans-arterial chemoembolization remains the standard for liver-confined intermediate-stage disease, and phase II/III trials including EMERALD-1 and LEAP-012 have shown progression-free survival gains from adding PD-1/PD-L1 blockade to TACE — though no overall survival benefit has yet been demonstrated and no European marketing authorisation exists for the combination. Selective internal radiotherapy (SIRT) with yttrium-90 microspheres, once dismissed after the negative SARAH and SIRveNIB trials, has been rehabilitated by the DOSISPHERE-01 study, which showed that personalised dosimetry delivering at least 205 Gy to the tumour significantly improves survival, even in patients with portal vein thrombosis. The prospective French PROACTIF registry of 989 patients reported 21.8-month median survival after SIRT, yet no randomised comparison with immunotherapy exists, leaving a widening gap between routine practice and guideline-endorsed standards.

The authors call for a coordinated, multi-stakeholder response: harmonised reimbursement pathways, prospective evidence for treatment sequencing, validated predictive biomarkers, broader access to clinical trials beyond academic centres through platforms such as the EU’s Clinical Trials Information System, and universal multidisciplinary review — potentially expanded through virtual networks supported by artificial intelligence. With HCC ranking thirteenth by incidence and sixth by mortality in Europe, the science has finally delivered survival gains once thought impossible. The remaining challenge, the review concludes, is no longer inventing effective treatments but ensuring that every European patient can actually receive them.

Subject of Research: Systemic and locoregional treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe

Article Title: Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe

Article References: Pinato, D. J., Alimenti, E., Lombardi, P., Vaz, J., Digklia, A., Edeline, J., Ben Khaled, N., Di Giacomo, E., Scheiner, B., Ramos, J. P., O’Kane, G. M., Cappuyns, S., Tesini, G., & Rimassa, L. (2026). Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe. The Lancet Regional Health – Europe, 70, Article 101839. https://doi.org/10.1016/j.lanepe.2026.101839

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101839

Keywords: hepatocellular carcinoma, immunotherapy, atezolizumab, bevacizumab, durvalumab, tremelimumab, tyrosine kinase inhibitors, EMA, reimbursement, health inequality, locoregional therapy, biomarkers